
|Videos|April 23, 2022
Orasis phase 2b data for CSF-1 presented at ASCRS
Author(s)Sheryl Stevenson
For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Noninvasive LED light therapy shows long-term safety in early cataract clinical follow-up
3
The Residency Report: PreserFlo microshunt vs trabeculectomy—five-year trial insights
4
IGS 2026: The expanding role of artificial intelligence in ophthalmology
5




























